Greenleaf Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Greenleaf Trust’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,125	Closed	-$390K	–	743
2021 Q2	$390K	Buy	2,125 +131	+7%	+$22.5K	﹤0.01%	476
2021 Q1	$305K	Buy	+1,994	New	+$308K	﹤0.01%	539
2018 Q1	–	Sell	-141	Closed	-$17K	–	682
2017 Q4	$17K	Sell	141 -28	-17%	-$3.41K	﹤0.01%	622
2017 Q3	$24K	Buy	+169	New	+$23K	﹤0.01%	544

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Greenleaf Trust's ALXN Position: Q3 2021 in Review

Greenleaf Trust sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,125 shares — an estimated $390K sold.

Greenleaf Trust first reported a position in ALXN in Q3 2017 and held it in 4 quarters. The position peaked at $390K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Greenleaf Trust reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Greenleaf Trust sold 2,125 Alexion Pharmaceuticals shares in Q3 2021, an estimated $390K.
Greenleaf Trust first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 4 quarters.
Greenleaf Trust's Alexion Pharmaceuticals position peaked at $390K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Greenleaf Trust's 13F filing for Q3 2021, filed 12 Nov 2021.